700 patients110,866 observations180 daysLIVE

Patient P-02157

Synthetic patientMETA-24 · Day 177 · 65–74 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S14
  2. Day 73 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 79 GI-04 recommendedGI Support Protocol GI-04
  4. Day 80 Patient declinedNot now
  5. Day 92 ME-01 recommendedMonitoring Escalation ME-01
  6. Day 93 Patient acceptedStarted ME-01 in the companion
  7. Day 96 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 73.

Primary contributors, last 14 days
  • Treatment adherence-8
  • Inflammatory activity-3

What helped?

  • GI Support Protocol GI-04Day 79
    Declined by patient
  • Monitoring Escalation ME-01Day 92
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 88% showed improvement
  • median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes
Wearable
16 min
improving · +1.6 vs previous 14 d
Sleep duration
Wearable
5.2 h
stable · -0.0 vs previous 14 d
Energy level
Daily log
2.1/10
improving · +0.1 vs previous 14 d
Steps
Wearable
1,818
improving · +449 vs previous 14 d
GI burden
Companion
71.6/100
stable · -1.9 vs previous 14 d
Adherence
Companion
37.7 %
worsening · -3.7 vs previous 14 d
Sleep quality
Wearable
10.1/100
stable · +0.3 vs previous 14 d
Glucose, CGM daily mean
CGM
158 mg/dL
stable · -2.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 33 from the failing basin, 70 from restoration.

Would help
  • GI-04 GI Support Protocol
    76% improved among 66 similar · onset 8 d · confidence 97%
  • NP-02 Dietary Support Protocol
    59% improved among 32 similar · onset 10 d · confidence 76%
  • SC-12 Supportive Compound
    69% improved among 26 similar · onset 6 d · confidence 76%
  • More protein
    GI -4.8 next day on high-intake days · n 21
Would not help
  • Keep fat low
    GI +4.2 next day on high-intake days · n 19
  • Keep histamine low
    GI +4.2 next day on high-intake days · n 19
  • Keep simple carbs low
    GI +2.9 next day on high-intake days · n 16
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Protein
    -4.8supporter · 95%
  • Dietary fat load
    +4.2detractor · 95%
  • Histamine load
    +4.2detractor · 95%
  • Simple carbohydrates
    +2.9detractor · 91%
  • Ultra-processed food
    +2.4detractor · 63%
  • Insoluble fibre
    +1.6no signal · 40%
  • Alcohol
    +1.6no signal · 40%
  • Caffeine
    -0.4no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 40/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Mucosal barrier integrity 60
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • Daily logGI symptom score 72 and rising
    • WearableSleep 5.2 h, below personal baseline
  • Inflammatory signalling 40
    • BloodInflammatory load index 61
    • WearableHRV 35 ms, trending down
  • Autonomic recovery 40
    • Wearable1,818 steps/day
    • WearableShort sleep window
  • Drug metabolism and exposure 20
    • BloodToxicity index 52
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Rapid metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2.7 · butyrate capacity 40/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
37 ms
Sleep
5.3 h
Steps
2,161
Resting HR
71 bpm
Daily log: GI score 72, nutritional resilience 32, adherence 38.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0253262%S1458
P-0232058%S14NP-02improved50
P-0251151%S0451
P-0234050%S14NP-02no change46
P-0259450%S2045
P-0234849%S14GI-04improved49
P-0237248%S14ME-01improved53
P-0251447%S05ME-01improved44
P-0253547%S14SC-12improved50
P-0262847%S14SC-12improved47
P-0257146%S11ME-01improved43
P-0259346%S14ME-01improved46